June 23, 2006 – Endo Pharma and Penwest Pharma have finally prevailed in a long-running battle to win FDA approval of an extended-release, oral formulation of oxymorphone. The new analgesic will be marketed under the Opana name. The ER version, which is expected to be the major producer of revenue, requires dosing only twice a day. We look at the history of the drug and its market potential...
